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Abstract: Ibuprofen- (IBU) loaded biocompatible poly(lactic-co-glycolic acid) (PLGA) films 
were prepared by spreading polymer/ibuprofen solution on the nonsolvent surface. By controlling 
the weight ratio of drug and polymer, different drug loading polymer films can be obtained. The 
synthesized ibuprofen-loaded PLGA films were characterized with scanning electron microscopy, 
powder X-ray diffraction, and differential scanning calorimetry. The drug release behavior of 
the as-prepared IBU-loaded PLGA films was studied to reveal their potential application in 
drug delivery systems. The results show the feasibility of the as-obtained films for controlling 
drug release. Furthermore, the drug release rate of the film could be controlled by the drug 
loading content and the release medium. The development of a biodegradable ibuprofen system, 
based on films, should be of great interest in drug delivery systems.
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Introduction
Nowadays, poly(lactic-co-glycolic acid) (PLGA) is widely applied in controlled 
drug delivery systems due to its biodegradability, toxicological safety, and good 
biocompatibility.1–5 Specifically, PLGA-based carriers have been used in long-term 
drug delivery systems because they have the potential to control drug release from a 
few days up to several months.6,7 In general, PLGA can degrade into water soluble, 
non-toxic products of normal metabolism through hydrolysis which is important 
for its practical application.8 Moreover, PLGA is one of the few synthetic polymers 
which have been approved for human clinical use. Several products such as Lupron 
Depot based on PLGA microparticles are available on the market.5,9 However, PLGA-
based carriers are mostly solid particles including nanoparticles, microparticles, and 
microcapsules, which have the disadvantages of low drug loading capacity, easy 
aggregation, and polydispersable particle sizes.10 Therefore, it is necessary to prepare 
aspherical carriers instead of particles. Various biocompatible and biodegradable 
polymer films have been widely used for controlled drug release due to their excellent 
characteristics, such as high surface area, softness, absorbency, and ease of fabrication 
into many product forms.11–16 Until now, a number of methods have been developed 
for fabrication of polymer films, such as layer-by-layer (LBL) method17 and solvent 
evaporation technique.18 However, the reported methods usually involve some 
cumbersome processing steps and are time-consuming. Therefore developing a simple 
route to prepare drug-loaded fibers is still a great challenge.
Ibuprofen (IBU) is classified by the Biopharmaceutics Classification System (BCS) 
as a Class II active pharmaceutical ingredient as it presents low solubility and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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high permeability.19 Thus, increasing the solubility of IBU to 
enhance its bioavailability is the major obstacle.20,21 Previous 
studies indicate that the formulated IBU microspheres have a 
high initial burst resulting from the accumulation of drug crystals 
on the surface of microspheres.8,22 In some cases, the formulated 
IBU microspheres are unsuitable for well controlled release.
In this paper we present a very simple and general route to 
prepare drug-loaded films.23,24 The biocompatible PLGA and 
IBU are used as the model polymer and drug, respectively. Both 
PLGA and IBU are dissolved in tetrahydrofuran (THF), and 
then 50 µL of the solution is injected on the surface of the water. 
PLGA and IBU are indissoluble in water while THF and water 
are mixable. Thus, the IBU-loaded PLGA film is obtained on 
the surface of water. Films with different drug-loading contents 
could be prepared by controlling the ratios of IBU and PLGA. 
The aims of this study are to prepare IBU-loaded PLGA films 
with a simple route, and to characterize these films for their 
potential applications in drug delivery systems.
Materials and methods
Materials
L-lactic acid (LA) and glycolic acid (GA) were purchased 
from Sinopharm Chemical Reagent Co. Ltd (Shanghai, 
China). PLGA was synthesized according to the literature.25 
The MW of PLGA (LA/GA = 75/25, MW = 80,000 g/mol) 
was determined by the inherent viscosity. IBU was bought 
from Aldrich. Double-distilled water was used in all the 
experiments. All chemicals were used as received.
Preparation of drug-loaded PLGA films
For a typical synthesis, appropriate amounts of PLGA and 
IBU were dissolved in tetrahydrofuran (THF). The weight 
ratio of THF/PLGA/IBU in the solution was WTHF/WPLGA/
WIBU = 85/12.5/2.5. A pipette was used to take 50 µL of the 
solution and then the solution was injected on the surface of 
distilled water in a beaker (the distance between the water 
surface and the drop source was 1 cm). The solution spread 
quickly on the surface of water and solidified into a film within 
3 seconds then the film was taken out at once and washed 
with distilled water and dried in air at 40°C. For the samples 
synthesized with different weight ratios, such as WTHF/WPLGA/
WIBU = 85/11.25/3.75 and WTHF/WPLGA/WIBU = 85/10/5, the 
synthetic procedures were similar to the above.
Drug loading and encapsulation efficiency
A certain amount of dried film was dissolved in 10 mL of 
THF. The UV absorbance of the solution was measured using 
a UV spectrophotometer at wavelength 264 nm which was 
a typical absorbance of IBU in THF. Pure THF was used 
for a blank experiment before the UV measurement. Drug 
loading content (DLC) and encapsulation efficiency (EE) 
were determined using the following equations.
DLC (%) = (IBU weight in film/film weight) × 100%  (1)
EE (%) = (actual weight of IBU/theoretical 
weight of IBU) × 100%   (2)
In vitro release studies
Three kinds of release mediums (phosphate buffered solution, 
PBS, pH = 6.8; phosphate buffered solution, PBS, pH = 7.4; 
and HCl aqueous solution, pH = 1.2) were used to study the 
in vitro release. In drug release studies, PBS was the typical 
medium to mimic intestinal fluid. The release of samples with 
different ratios (WTHF/WPLGA/WIBU = 85/12.5/2.5, WTHF/WPLGA/
WIBU = 85/11.25/3.75, and WTHF/WPLGA/WIBU = 85/10/5) were 
performed in 50 mL PBS (pH 6.8). The influence of the release 
medium on the sample (WTHF/WPLGA/WIBU = 85/12.5/2.5) was 
performed in 50 mL HCl solution (pH 1.2) and PBS (pH 
7.4), respectively. The in vitro experiments were carried 
out in a heated bath at 37°C in triplicate. The sample was 
sealed in a dialysis bag (from Solarbio, Beijing, China), 
which was suspended in 50 mL release medium in a sealed 
beaker under continuous stirring at a rate of 100 rpm.26,27 
At predetermined time intervals, 1.5 mL of the resultant 
release medium was sampled for analysis, then 1.5 mL of 
fresh release medium was immediately added to maintain 
the original volume. Based on the standard curve, the IBU 
concentration in the sampled release medium was obtained 
through UV experiment (λ = 222 nm).
The cumulative amount of IBU released from the samples 
was calculated using the equation:
Cumulative amount released (%) = Mt/Mtotal × 100%
Mt was the amount of IBU released from the PLGA films 
at time t and Mtotal was the total amount of IBU loaded in the 
PLGA films.
Drug release kinetics
The kinetics of IBU release from the films were determined 
by fitting different curves to distinct models. The models 
included Zero order, First order, Higuchi release model, 
Ritger-Peppas, and Biexponential model. The linear form of 
each function was evaluated using R regression analysis.
seM
Scanning electron microscopy (SEM) was done using 
a Hitachi SU-70 FESEM scanning electron microscope International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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operated at 3 kV . Samples were sputtered with Au prior to 
imaging (the thickness of Au was 5 nm).
X-ray diffraction (XrD) measurements
XRD measurements were obtained on a Rigaku Dmax-rc 
X-ray diffractometer with Ni filtered Cu Kα radiation. The 
angular range was from 10° to 60°.
Dsc measurements
Differential scanning calorimetry (DSC) measurements were 
performed using CDR-4P (Shanghai Precision and Scientific 
Instrument Co., Ltd. China). Weighed samples of 5 mg were 
placed in aluminum pans and the samples were scanned from 
40°C to 200°C using a heating rate of 10°C/min.
Results and discussion
Drug loading and encapsulation efficiency
The results of drug loading and encapsulation efficiencies 
with different WTHF/WPLGA/WIBU ratios are shown in Table 1. 
The drug loading contents for the samples of WTHF/WPLGA/
WIBU = 85/12.5/2.5, WTHF/WPLGA/WIBU = 85/11.25/3.75, and 
WTHF/WPLGA/WIBU = 85/10/5 are 14.7% ± 0.2%, 22% ± 1.6% 
and 29.7% ± 0.4%, respectively. The values are a little smaller 
than the corresponding ones in theory (16.7%, 25%, and 
33.3%, respectively). As for the encapsulation efficiency, the 
samples exhibit high percentages (more than 88%) and there 
are no remarkable differences among the different samples. 
These results reveal that our method is a simple and efficient 
way to prepare films with high drug loading and encapsulation 
efficiency. The high drug loading and encapsulation efficiency 
can be explained by the solubility of IBU and PLGA in THF, 
but their insolubility in water. THF, however, is intersoluble 
with water. When the mixed solution spreads on the water 
surface, the THF molecules immediately diffuse into the 
water phase, leaving the PLGA and IBU molecules to quickly 
solidify due to their indissolubility in water. Thus, high drug 
loading and encapsulation efficiency are obtained.
electron microscopy
Figure 1 shows SEM images of the IBU-loaded PLGA 
film with the ratio of WTHF/WPLGA/WIBU = 85/12.5/2.5. 
Figure 1A exhibits the top surface of the film, which has 
a convex pattern. The diameter of each convex shape is 
1.52 ± 0.45 µm. Figure 1B shows a cross-section image of 
the film, which has a smooth surface, indicating the absence 
of a void in the film.
Figure 2 shows the SEM images of films with different 
ratios of WTHF/WPLGA/WIBU. Figure 2A shows the film with a 
ratio of WTHF/WPLGA/WIBU = 85/11.25/3.75. It shows that the 
film has a convex pattern on the top surface. The diameter of 
each convex shape is 0.87 ± 0.11 µm. The insert in Figure 2A 
shows the rough cross-section surface which indicates the 
presence of voids in the film. Figure 2B shows the film with 
a ratio of WTHF/WPLGA/WIBU = 85/10/5. The top surface is 
relatively smooth and has no convex pattern. Furthermore, 
the cross-section of the film is rough, which indicates that 
there are voids in the film.
The SEM images in Figure 1 and Figure 2 show 
that there are voids in the film formed with higher drug 
concentration (WTHF/WPLGA/WIBU = 85/11.25/3.75 and 
WTHF/WPLGA/WIBU = 85/10/5) while there are no obvious 
voids in the film formed at lower drug concentration 
(WTHF/WPLGA/WIBU = 85/12.5/2.5). There is a convex pattern 
in the samples of WTHF/WPLGA/WIBU = 85/12.5/2.5 and WTHF/
WPLGA/WIBU = 85/11.25/3.75. However, there is no convex 
pattern for the sample of WTHF/WPLGA/WIBU = 85/10/5. The 
convex-patterned surface may result from the surface tension 
Table 1 Drug loading and encapsulation efficiency (%) at various 
IBU/PLgA weight ratios (±sD, n = 3)
Ratio of WTHF/WPLGA/WIBU 85/12.5/2.5 85/11.25/3.75 85/10/5
Drug loading (%) 14.7 ± 0.2 22.0 ± 1.6 29.7 ± 0.4
Theoretical loading (%) 16.7 25 33.3
Encapsulation efficiency (%) 88.2 ± 1.2 88.0 ± 6.6 89.1 ± 1.3
Abbreviations: IBU, ibuprofen; PLgA, poly(lactic-co-glycolic acid).
A B
5 µm 5 µm
Figure 1 SEM images of IBU-loaded PLGA films (WThF/WPLgA/WIBU = 85/12.5/2.5), 
the surface (A), and the thickness (B).
Abbreviations: IBU, ibuprofen; PLgA, poly(lactic-co-glycolic acid); seM, scanning 
electron microscopy.
AB
5 µm5  µm
1 µm
1 µm
Figure 2 SEM images of IBU-loaded PLGA films, WThF/WPLgA/WIBU = 85/11.25/3.75 (A) 
and WThF/WPLgA/WIBU = 85/10/5 (B).
Abbreviations: IBU, ibuprofen; PLgA, poly(lactic-co-glycolic acid); seM, scanning 
electron microscopy.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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when the phase separation proceeds at the top surface of 
the polymer solution, ie, the air/solution interface.24 The 
films have a dimension of about 33 cm2, which is as large as 
the Baker’s dimension. The thickness of all the films with 
different weight ratios is in the range of 2 to 5 µm. In short, the 
ratio of WTHF/WPLGA/WIBU has a large influence on the surface 
morphology and structure of the films. For the formation of 
IBU-loaded PLGA film, the THF solvent diffuses quickly 
into water which leaves the undissolved IBU and PLGA 
solidified. In this case, the IBU and PLGA form a thin film 
on the surface of water. It is known that IBU and PLGA can 
dissolve well in THF as molecular state, and therefore the 
drug is distributed homogenously in the formed films.
XrD measurements
X-ray diffraction (XRD) patterns were established on the pure 
IBU, pure PLGA, and the IBU-loaded PLGA films, in order 
to study the physical state of these systems. Generally, when 
the patterns of two crystal forms are identical in terms of 
peak positions, they have the same internal crystal structure, 
whereas if the patterns differ, the crystals have a different 
internal structure and are recognized as polymorphs.28 The 
XRD pattern of pure PLGA shown in Figure 3a has no evident 
brand, which denotes an amorphous polymeric compound. 
Figure 3b shows the XRD patterns of pure IBU, which yields 
typical peaks at 16°, 20°, and 22°, showing the crystalline 
substance. In the curves of IBU-loaded PLGA films shown in 
Figure 3c, d, and e, peaks at 16°, 20°, and 22° were detected 
in the three samples, which demonstrates that IBU had a 
crystalline state in the film. The difference in the relative 
intensity of the peaks is due either to the variation of the 
crystal habit, because the relative abundance of the planes 
exposed to X-ray source is altered, or to differences in the 
size of the crystals.28
Dsc measurements
In order to further study the drug–polymer interaction, the 
DSC thermal characteristics of IBU-loaded PLGA films 
(c, d, and e) are compared with pure PLGA (a) and pure IBU 
(b) in Figure 4. The endothermic peak of PLGA (curve a) 
is observed at 56°C, which can be attributed to the glass-
transition temperature of PLGA. The curve in Figure 4 shows 
a sharp endothermic peak at 78°C, which indicates that the 
melting peak of pure IBU is 78°C. The curves c, d, and e 
in Figure 4 show the peaks of different drug-loading films. 
Comparing with pure IBU, the melting points are 65, 75, and 
73 for the samples of WTHF/WPLGA/WIBU = 85/12.5/2.5, WTHF/
WPLGA/WIBU = 85/11.25/3.75 and WTHF/WPLGA/WIBU = 85/10/5, 
respectively. The shift of the melting point indicates a 
decrease of drug crystallinity. These results are consistent 
with the XRD analysis, which reveals that IBU is crystalline 
while PLGA is amorphous in the drug-loaded film.
In vitro release studies
We examined the drug release behaviors of the as-prepared 
IBU-loaded PLGA films, in order to reveal their potential use 
in drug delivery systems. Figure 5 shows the release profiles 
of pure IBU and different ratios of WTHF/WPLGA/WIBU films in 
phosphate buffered solution (PBS, pH 6.8). Curve (a) shows 
that the pure IBU releases rapidly into the release medium 
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Figure 3 XrD patterns of: a) pure IBU, b) PLGA, and IBU-loaded PLGA films: 
c) WThF/WPLgA/WIBU = 85/12.5/2.5; d) WThF/WPLgA/WIBU = 85/11.25/3.75 and e) WThF/
WPLgA/WIBU = 85/10/5.
Abbreviations: IBU, ibuprofen; PLgA, poly(lactic-co-glycolic acid); XrD, X-ray 
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Figure 4 Dsc curves of PLgA (a), pure IBU (b), and IBU-loaded films: c) WThF/
WPLgA/WIBU = 85/12.5/2.5; d) WThF/WPLgA/WIBU = 85/11.25/3.75 and (e) WThF/WPLgA/
WIBU = 85/10/5.
Abbreviations:  Dsc,  differential  scanning  calorimetry;  IBU,  ibuprofen;  PLgA, 
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with a release mount of nearly 100% in 12 hours. In contrast, 
in the sample with a ratio of WTHF/WPLGA/WIBU = 85/12.5/2.5, 
the release reached 12.7% ± 1.5% within 24 hours, and 
reached 32.4% ± 7.8% in 120 hours. In the sample with a ratio 
of WTHF/WPLGA/WIBU = 85/11.25/3.75, the release rate reached 
27.5% ± 6.4% in 24 hours and 60% ± 5.5% in 120 hours. 
However, the release reached 46.6% ± 9.5% in 24 hours and 
65.3% ± 1.6% in 120 hours in the sample with a ratio of 
WTHF/WPLGA/WIBU = 85/10/5. The different release percentages 
over the same time, show that the release rate decreases as 
the drug loading decreases. This can be due to the fewer drug 
molecules diffusing through the polymer network with the 
decrease of the drug loading. The polymer network becomes 
more porous as the drug concentration decreases, so that 
the soluble IBU molecules have to travel a longer distance 
from the pores to the release medium. The burst effect is not 
observed in the release, which can be explained as follows. 
On the one hand, the IBU is distributed homogeneously in 
the polymer without much surface segregation. On the other 
hand, rinsing the film decreases the amount of drug associated 
on the surface. These results show that a more controlled 
release can be obtained when changing the weight ratio of 
the drug, which indicates the potential application of the 
as-prepared drug-loaded PLGA products in a drug controlled 
delivery system.
In order to better understand the importance of the release 
mediums on the drug release kinetics from PLGA-based 
films, the other two release mediums were chosen to mimic 
the in vitro release. Figure 6 shows the release profiles of the 
sample with WTHF/WPLGA/WIBU = 85/12.5/2.5 from the release 
mediums, HCl aqueous solution (pH 1.2) and PBS (pH 7.4). 
The time to reach 30% of drug release in PBS was 135 hours 
compared with 238 hours in HCl aqueous solution, which 
reveals that the drug release kinetic is faster at high pH than 
at low pH. The decreased release rate of IBU in acidic media 
(pH 1.2) may have been due to the decreased solubility of 
IBU. The pKa of IBU is known to be 4.42 and thus it has low 
aqueous solubility when the pH of the medium is below or 
close to 4.42. What is more, matrix erosion which is affected 
by medium pH is also expected to affect the drug release. 
It is known that PLGA hydrolysis is equilibrium-limited in 
acidic environments, while it is not limited by equilibrium 
in basic conditions. Thus the erosion of the matrix increases 
when the pH of the release medium increases.
Drug release kinetics
The kinetics of IBU release from the films are determined by 
fitting the curves to distinct models, Zero order, First order, 
Higuchi release model, Ritger-Peppas, and Biexponential 
model. The equations for the different models and the 
regression coefficient (R) are given in Table 2 and the best-fit 
model is selected on the basis of R.
For the sample WTHF/WPLGA/WIBU = 85/12.5/2.5 in pH 
7.4 PBS and WTHF/WPLGA/WIBU = 85/10/5 in pH 6.8 PBS, we 
observe that R value is larger when fitted to a biexponential 
equation compared with other equations, which indicates a 
biexponentia release from the PLGA-based films. The R value 
is higher when the samples (WTHF/WPLGA/WIBU = 85/12.5/2.5 
and WTHF/WPLGA/WIBU = 85/11.25/3.75) are fitted to the Ritger-
Peppas kinetics equation in the pH 6.8 release medium, 
which indicates a Ritger-Peppas release from the PLGA 
matrix. When the sample (WTHF/WPLGA/WIBU = 85/12.5/2.5) 
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is released from pH 1.2 release medium, it fits to Zero-order 
kinetics. As for the release of pure IBU, the R value is larger 
when fitting to First-order kinetics than Zero-order kinetics. 
Drug release from matrices is usually complex and though 
some processes may be clearly classified as either diffusion 
or erosion controlled, drug release is mostly governed by 
both mechanisms. However, the above results may provide 
a better understanding of the drug controlled release from 
the drug-loaded films.
Conclusion
In summary, a very simple, basic method was developed 
to fabricate drug-loaded biocompatible polymeric films by 
directly spreading polymer/drug solution on the nonsolvent 
surface. PLGA and IBU were used as the model polymer 
and drug, respectively. By controlling the weight ratio of 
IBU and PLGA, different drug loading percentage films can 
be prepared. The drug release behaviors of the as-prepared 
products show their potential applications in a drug 
controlled delivery system. The release rate of IBU from 
these films into phosphate buffered solutions appeared to 
depend on a number of factors including drug loading content 
and the pH of the release mediums. This method can easily 
be scaled up and potentially extended to the fabrication of 
other drug-loaded composites for the application in drug 
delivery systems.
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Table 2 The equations for the different models and the regression coefficient (R) of IBU-loaded PLGA films in vitro
Samples Model Equation R
WThF/WPLgA/WIBU =  85/12.5/2.5, ph = 1.2 Zero-order kinetics Q = 0.1201 t + 3.0237 0.9972
First-order kinetics ln(100- Q) = −0.0014 t + 4.5786 0.9970
higuchi Q = 1.6027 t1/2 − 1.3078 0.9085
ritger-Peppas ln Q = 0.4062 lnt + 0.6594 0.9528
Biexponential 100- Q = 97.839e−0.1052t + 104e−0.139t Rα = 0.9340
Rβ = 0.9690
WThF/WPLgA/WIBU = 85/12.5/2.5, ph = 7.4 Zero-order kinetics Q = 0.2057 t + 4.2613 0.9956
First-order kinetics ln(100- Q) = −0.003 t + 4.5832 0.9830
higuchi Q = 3.2695 t1/2 − 3.0312 0.9654
ritger-Peppas ln Q = 0.5008 lnt + 0.9880 0.9894
Biexponential 100- Q = 98.283e−1.0574t + 94.796e−0.2002t Rα = 0.9834
Rβ = 0.9957
WThF/WPLgA/WIBU = 85/12.5/2.5, ph = 6.8 Zero-order kinetics Q = 0.2281 t + 6.3468 0.9920
First-order kinetics ln(100- Q) = −0.0028 t + 4.5497 0.9953
higuchi Q = 2.8396 t1/2 + 0.1087 0.9948
ritger-Peppas ln Q = 0.4659 lnt + 1.1722 0.9955
Biexponential 100- Q = 96.181e−0.5508t + 91.87e−0.2075t Rα = 0.9857
Rβ = 0.9945
WThF/WPLgA/WIBU = 85/11.25/3.75, ph = 6.8  Zero-order kinetics Q = 0.4216 t + 12.675 0.9736
First-order kinetics ln(100- Q) = −0.0067 t + 4.4868 0.9896
higuchi equation Q = 5.3614 t1/2 + 0.5101 0.9953
ritger-Peppas ln Q = 0.4993 lnt + 1.6995 0.9973
Biexponential 100- Q = 93.85e−1.0107t + 80.762e−0.3462t Rα = 0.9933
Rβ = 0.9862
WThF/WPLgA/WIBU = 85/10/5, ph = 6.8 Zero-order kinetic Q = 0.235 t + 28.738 0.9369
First-order kinetics ln(100- Q) = −0.0052 t + 4.2746 0.9761
higuchi equation Q = 4.4906 t1/2 + 13.555 0.9801
ritger-Peppas ln Q = 0.4194 lnt + 2.1991 0.9826
Biexponential 100- Q = 90.346e−1.52t + 50.022e−0.1150t rα = 0.9968
rβ = 0.9945
Pure IBU, ph = 6.8 Zero-order kinetics Q = 6.4129 t + 35.624 0.7701
First-order kinetics ln(100- Q) = −0.2586 t + 4.1051 0.9510
Note: Where Q is the fraction of drug release, t is the time, R is the regression coefficient.International Journal of Nanomedicine
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